Trending...
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano
- Governor Newsom marks historic expansion of California's Film and Television Tax Credit Program, announces 16 new projects to film in the Golden State
- California: Governor Newsom announces appointments 7.2.25
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) securities between June 1, 2021 and November 4, 2021, for violations of the Securities Exchange Act of 1934. NRx is a clinical-stage pharmaceutical company that develops therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The Company's products include, among others, ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure.
If you suffered a loss due to NRx Pharmaceuticals, Inc.'s misconduct, click here.
More on The Californer
NRx Pharmaceutical, Inc. (NRXP) Misled Investors Regarding the EAU Status of its Drug Candidate
According to the complaint, in June 2021, NRx announced it had filed an application with the U.S. Food and Drug Administration ("FDA") requesting Emergency Use Authorization ("EUA") for ZYESAMI to treat critically ill COVID-19 patients suffering with respiratory failure. However, defendants failed to disclose that the ZYESAMI EUA application contained insufficient data regarding the potential benefits and risks of the drug and therefore, the FDA was unlikely to approve the ZYESAMI EUA application in its present form.
On November 4, 2021, NRx issued a press release announc[ing] that the [FDA] has declined to issue an [EUA] for ZYESAMI® (aviptadil). The FDA stated that it was unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of ZYESAMI in patients suffering from Critical COVID-19 with respiratory failure." On this news, NRx's stock price fell $2.27 per share or over 25%, to close at $6.65 per share on November 5, 2021.
If you purchased shares of NRx Pharmaceutical, Inc. (NRXP) between June 1, 2021 and November 4, 2021, you have until March 21, 2022, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
More on The Californer
Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against NRx Pharmaceutical, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Aaron Dumas
Robbins LLP
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com
If you suffered a loss due to NRx Pharmaceuticals, Inc.'s misconduct, click here.
More on The Californer
- California: Governor Newsom announces deployment of urban search and rescue task force teams to Texas
- Long Beach Youth Invited to Apply for the City's Youth Advisory Council
- Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
- Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
- Amid Trump's assault on public lands, California conserves over one million acres of land and coastal waters in just one year
NRx Pharmaceutical, Inc. (NRXP) Misled Investors Regarding the EAU Status of its Drug Candidate
According to the complaint, in June 2021, NRx announced it had filed an application with the U.S. Food and Drug Administration ("FDA") requesting Emergency Use Authorization ("EUA") for ZYESAMI to treat critically ill COVID-19 patients suffering with respiratory failure. However, defendants failed to disclose that the ZYESAMI EUA application contained insufficient data regarding the potential benefits and risks of the drug and therefore, the FDA was unlikely to approve the ZYESAMI EUA application in its present form.
On November 4, 2021, NRx issued a press release announc[ing] that the [FDA] has declined to issue an [EUA] for ZYESAMI® (aviptadil). The FDA stated that it was unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of ZYESAMI in patients suffering from Critical COVID-19 with respiratory failure." On this news, NRx's stock price fell $2.27 per share or over 25%, to close at $6.65 per share on November 5, 2021.
If you purchased shares of NRx Pharmaceutical, Inc. (NRXP) between June 1, 2021 and November 4, 2021, you have until March 21, 2022, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
More on The Californer
- California: Governor Newsom announces appointments 7.7.25
- City of Long Beach to Upgrade Its Internet Infrastructure to Enhance City Network Reliability and Performance
- Groflex Named One of the Top 100 Manufacturing Startups in San Francisco by F6S
- BofA Directs Additional $1 Million to Los Angeles Nonprofits for Evolving Fire Recovery Needs
- Introducing LK Blue: The Cool-Girl Denim Brand That's Redefining LA Style Launches E-Commerce
Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against NRx Pharmaceutical, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Aaron Dumas
Robbins LLP
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com
Filed Under: Business
0 Comments
Latest on The Californer
- Swim Up Hill Games Launches Beta Version of Runner-Style Swim Game to Advance Global Water Safety
- Swim Up Hill, California Science Center Launch First Virtual Swim Experience in LA84-Funded Exhibit
- California: TOMORROW: Governor Newsom to join federal, state, and local leaders to recognize six-month anniversary of Los Angeles firestorms
- Skool Alternatives Reddit: Skool vs Circle vs Whop - Did you join one yet?
- Southern Soul Artist Moe Z Releases New Single 'Set It Out' Distributed by Morris Day Entertainment
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
- Green Jacket Gateway" System: Your Definitive Path to Golfing Greatness
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- Luxury Auto Detailing Brings High-End Mobile Car Care to Cherry Valley and Surrounding Areas
- Transgender Visual Artist Debuts New Work
- Stay Cool All Day With BGMgirl Drawstring Half Wigs
- California: Governor Newsom proclaims Independence Day 2025
- Gundam GQuuuuuuX Takes Center Stage at Anime Expo 2025
- John Duffy Competes in Mr Muscle Beach
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Thorn & Bloom Magazine Unveils Groundbreaking Second Edition: "Breaking the Cycle"
- Cheap O SMS Launches Groundbreaking Free SMS API Service
- California: Governor Newsom signs legislation 7.3.25
- Fireworks, fun, and safety: California preps for the holiday weekend
- BillBoards Inc. Hits the Road with God Bless America Tour and Reality Series Now Streaming on Tubi TV